Clinical Trials Browser

Phase 2 × Congenital Abnormalities × Azacitidine × Clear all

NCT01869114 2025-12-10

Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy

Phase 2 Completed

57 enrolled 13 charts

Other hematologic neoplasm

Chromosome 5q Deletion Syndrome, Congenital Abnormalities, Leukemia, Myeloid, Acute

NCT01707004 2019-11-21

Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 2 Completed

20 enrolled 19 charts

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute

NCT01083706 2017-05-24

Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant

Phase 2 Completed

43 enrolled 7 charts

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT00739388 2013-04-10

Azacitidine in Treating Patients With Newly Diagnosed Previously Untreated or Secondary Acute Myeloid Leukemia Who Are Unsuitable For Intensive Chemotherapy

Phase 2 Completed

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute